8 th InterAmerican Oncology Conference 'Current Status and Future of Anti-Cancer Targeted Therapies' October 17-18, 2019 Buenos Aires, Argentina

Transcription

1 FIRST ANNOUNCEMENT 8 th InterAmerican Oncology Conference 'Current Status and Future of Anti-Cancer Targeted Therapies' October 17-18, 2019 Buenos Aires, Argentina The 8 th Conference of IAOC "Current Status and Future of Anti-Cancer Targeted Therapies" will be held in Buenos Aires, Argentina in October 17 th and 18 th, An outstanding faculty of speakers from the United States and Europe has committed in this meeting. The conference agenda will focus on new translational advances in the treatment of cancer as well as provide updates of conventional therapies for a number of the most common tumor types. The meeting objectives are designed to introduce the audience to the latest information on targeted therapies, immunotherapies and emerging treatments in early development. The major emphasis will be on clinical aspects of cancer treatment in the 21 st century with discussion of significant scientific advances underlying the novel approaches still in preclinical development. This meeting is the primary opportunity for oncologists, hematologists and cancer related health workers to participate in a conference focusing on novel targeted therapies and other treatment advances which are changing the face of cancer care. CO- CHAIRS Alex Adjei, Rochester, USA Román Perez Soler, New York, USA Antoni Ribas, Los Angeles, USA ORGANIZING COMMITTEE Román Pérez Soler, New York, USA Andrea Blanco, Buenos Aires, Argentina SCIENTIFIC COMMITTEE Alex Adjei, M.D., Ph.D., Mayo Clinic, Rochester, USA Kenneth C. Anderson, M.D., Dana-Farber Cancer Institute Boston, Massachusetts, USA Carlos L. Arteaga, M.D., Harold C. Simmons Cancer Center, Texas, USA Roman Perez Soler, M.D., Albert Einstein College of Medicine, New York, USA Antoni Ribas, M.D., Ph.D., UCLA, Los Angeles, USA Josep Tabernero, M.D., Ph.D., Vall d'hebron University Hospital, Barcelona, Spain

2 FACULTY (PROVISIONARY) Alex A. Adjei, M.D., Ph.D. Consultant in Oncology Professor of Oncology Mayo Clinic Rochester, Minnesota, USA Kenneth C. Anderson, M.D. Kraft Family Harvard Medical School Dana-Farber Cancer Institute Boston, Massachusetts, USA Stephen M. Ansell, M.D., Ph.D. Chair Lymphoma Group Mayo Clinic Rochester, Minnesota, USA Carlos L. Arteaga, M.D. and Cancer Biology Director, UTSW Harold C. Simmons Cancer Center Associate Dean of Oncology Lisa K. Simmons Distinguished Chair in Comprehensive Oncology Dallas, Texas, USA Carlos H. Barrios, M.D. Hospital do Cancer Mãe de Deus Porto Alegre RS, Brazil Joaquim Bellmunt, M.D., Ph.D. Associate Professor, Medicine, Harvard Medical School Bladder Cancer Center Dana-Farber Cancer Institute Boston, Massachusetts, USA Jorge Cortés, M.D. Chief, CML & AML Sections Deputy Chair, Department of Leukemia M.D. Anderson Cancer Center Houston, Texas, USA 2

3 Charles Drake, M.D., Ph.D. * Co-Director, Cancer Immunotherapy Programs Director of genitourinary oncology Herbert Irving Comprehensive Cancer Center Columbia University Medical Center NY, New York, USA Román Pérez-Soler, M.D. Chairman, Department of Oncology Montefiore Medical Center and Molecular Pharmacology Deputy Cancer Center Director Albert Einstein College of Medicine Bronx,, New York, USA Gabriel A. Rabinovich, Ph.D. * Head of the Laboratoy of Immunopathology Instituto de Biología y Medicina Experimental (IBYME) Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) Member of the USA National Academy of Sciences Buenos Aires, Argentina Antoni Ribas, M.D., Ph.D. and Surgery Professor of Molecular and Medical Pharmacology Director Tumor Immunology Program, Jonsson Comprehensive Cancer Center (JCCC) David Geffen School of Medicine, UCLA Chair, Melanoma Committee at SWOG Los Angeles, California, USA Josep Tabernero, M.D., Ph.D., Chairman Medical Oncology Department Vall d'hebron University Hospital Barcelona, Spain *TBC (to be confirmed) 3

4 PRELIMINARY PROGRAM NEW ANTICANCER THERAPIES Promising Novel Agents in Early Clinical Trials: Alex A. Adjei, Rochester, USA Novel Combination Approaches for Cancer Immunotherapy: TBA Immune Checkpoint Inhibitors for Melanoma: Antoni Ribas, California, USA Emerging Checkpoints in Immune and Vascular Signaling Programs in Cancer: Gabriel Rabinovich, Buenos Aires, Argentina (*TBC) Cancer Biomarkers: Antoni Ribas, California, USA The Evolution of Cancer Immunotherapy: Ignacio Melero, Pamplona, Spain (*TBC) BREAST CANCER New Drugs and treatments in Breast Cancer: Carlos L. Arteaga, Texas, USA Challenges in the Genomic Selection of Patients: Carlos Barrios, Porto Alegre, Brazil GU CANCER Novel Therapies in Prostate and Renal Cancer: Charles Drake, Columbia, USA (*TBC) The Evolution of Targeted Therapy and Checkpoint Inhibitors in Bladder Cancer: Joaquim Bellmunt, Barcelona, Spain GI CANCER Novel Therapies in Gastric Cancer: Josep Tabernero, Barcelona, Spain 4

5 New Treatment for Colorectal Cancer: Josep Tabernero, Barcelona, Spain LUNG CANCER What s new in the Management of SCLC: Alex A. Adjei, Rochester, USA Current Management of NSCLC: Román Pérez Soler, New York, USA Combination Immunotherapy for Lung Cancer: TBA HEMATOLOGICAL MALIGNANCIES New Developments in Lymphoma: Stephen Ansell, Rochester, USA Multiple Myeloma: Kenneth C. Anderson, Boston, USA Novel Drug Development in Leukemia: Jorge Cortés, Houston, USA CONFERENCE SECRETARIAT AND INFORMATION secretariat@oncologyconferences.com.ar Web: 5